News | August 25, 2024
BioIVT acquires ZenBio
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
The emergence of new infections in India is a growing concern
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
